A detailed history of Sg Americas Securities, LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 8,235 shares of ARCT stock, worth $136,124. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,235
Holding current value
$136,124
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$18.08 - $25.38 $148,888 - $209,004
8,235 New
8,235 $191,000
Q1 2024

May 06, 2024

SELL
$31.23 - $42.99 $765,759 - $1.05 Million
-24,520 Reduced 73.68%
8,758 $296,000
Q4 2023

Jan 12, 2024

SELL
$17.71 - $32.97 $753,861 - $1.4 Million
-42,567 Reduced 56.12%
33,278 $1.05 Million
Q3 2023

Oct 13, 2023

BUY
$25.44 - $37.35 $1.93 Million - $2.83 Million
75,845 New
75,845 $1.94 Million
Q1 2023

Apr 28, 2023

BUY
$14.72 - $23.97 $148,465 - $241,761
10,086 New
10,086 $242,000
Q2 2022

Jul 29, 2022

BUY
$12.26 - $31.17 $278,032 - $706,873
22,678 New
22,678 $357,000
Q1 2022

Apr 29, 2022

SELL
$17.64 - $39.57 $105,222 - $236,035
-5,965 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$34.2 - $47.56 $301,028 - $418,623
-8,802 Reduced 59.61%
5,965 $221,000
Q3 2021

Nov 01, 2021

BUY
$27.88 - $58.25 $411,703 - $860,177
14,767 New
14,767 $706,000
Q2 2021

Aug 12, 2021

SELL
$25.79 - $42.11 $189,685 - $309,719
-7,355 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$38.75 - $86.92 $285,006 - $639,296
7,355 New
7,355 $304,000
Q4 2020

Feb 04, 2021

SELL
$34.61 - $123.66 $620,591 - $2.22 Million
-17,931 Closed
0 $0
Q3 2020

Nov 09, 2020

BUY
$37.49 - $63.19 $395,556 - $666,717
10,551 Added 142.97%
17,931 $769,000
Q2 2020

Jul 20, 2020

BUY
$12.66 - $58.27 $93,430 - $430,032
7,380 New
7,380 $345,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $439M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.